Uncategorized
Omeros Corporation Reaches Agreement with FDA on OMS721 Phase 3 Trial Protocol for IgA Nephropathy
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that it has reached agreement with the US Food and Drug Administration (FDA) on Omeros’ protocol for its Phase 3 clinical trial evaluating OMS721 in patients with IgA nephropathy (IgAN). Patient enrollment is expected to begin early next month. The single Phase 3 trial is a randomized, double-blind, placebo-controlled trial in patients at least 18 years of age with biopsy-confirmed IgAN and with 24-hour urine protein ex